Bayer Expands Global Clinical Program for Darolutamide in Prostate Cancer

The new Phase III clinical study, ARASTEP, would investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.